Lakewood-Amedex Biotherapeutics Inc. LABT
—
1.67
(0.16)
(8.74%)
as of 25 Sep
- Market cap
- $4.3M
- P/E
- 0.0×
Follow LABT
| Jun '26 | Mar '26 | Dec '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
| 0.00% | — | — | — |
+2 more TTM periods Free account |
|
| (302.50%) | 0.00% | — | — | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(177.63%) | 0.00% | 0.00% | — | |
Average Days of Receivables |
0.00 | — | — | — | |
Free Cash Flow per Share |
(3.46) | (4.59) | 0.00 | 0.00 | |
Free Cash Flow |
(4.91) | (3.21) | (8.58) | — | |
Piotroski F-Score |
1.00 | — | — | — | |
| Other line items | |||||
Cash ROIC |
(55.04%) | 113.34% | 496.53% | 0.00% | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | — | |
Tax Rate |
0.00 | — | — | — | |
Research and Development Expense of Revenue |
0.00% | — | — | — | |
Selling, General and Administrative Expense of Revenue |
0.00% | — | — | — | |
Share Based Compensation of Revenue |
0.00% | — | — | — | |
Interest Coverage |
0.00 | — | — | — | |
Operating CF/Net income |
0.65 | 0.00 | 0.00 | — | |
Depreciation/Fixed assets |
30.59 | 25.94 | 25.18 | — | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | — | |
Revenue per Share |
0.00 | 0.00 | — | 0.00 | |
Operating CF per Share |
(3.46) | (4.59) | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | — | 0.00 | |
Net Profit Margin |
0.00% | — | — | — |
Columns are period end dates